{
    "clinical_study": {
        "@rank": "23257", 
        "arm_group": {
            "arm_group_label": "Laser+Methylaminolevulinat", 
            "arm_group_type": "Experimental", 
            "description": "It's a single arm. Intervention as described in the detailed description."
        }, 
        "brief_summary": {
            "textblock": "The objectives of this study is to investigate if pre-treating the skin with an ablative\n      fractional laser that creates small micropores in the skin:\n\n        1. Increases the uptake of Methylaminolevulinat (MAL) in the skin.\n\n        2. Decreases the required incubation time of MAL when performing photo dynamic therapy."
        }, 
        "brief_title": "Optimizing Uptake of Methylaminolevulinat With Fractional Ablative Laser Technique", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Photo Dynamic Therapy", 
            "Ablative Fractional Laser"
        ], 
        "detailed_description": {
            "textblock": "12 healthy male individuals were included.\n\n      On the back, 25 areas measuring 2.8x2.8 cm were marked, plus one control area. We tested 2\n      variables.\n\n      1) Density of laser channels. 2) Methylaminolevulinat (MAL) concentration\n\n        1. Laser - Each area was randomized to receiving:\n\n             -  no treatment\n\n             -  1% laser channel density\n\n             -  2% laser channel density\n\n             -  5% laser channel density\n\n             -  10% laser channel density\n\n             -  15% laser channel density\n\n        2. MAL - Each density was assigned to 4 areas. Within each density category, the four\n           areas were randomized to receive:\n\n             -  vehicle\n\n             -  4% MAL\n\n             -  8%MAL\n\n             -  16%MAL\n\n      The uptake of MAL was evaluated by fluorescence intensity measured with a florescence camera\n      at t=\n\n        -  0min\n\n        -  30min\n\n        -  1h\n\n        -  1.5h 2h 2.5h 3h"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male\n\n          -  >18 years old\n\n          -  Fitzpatrick skin type I-III\n\n          -  No UV exposure thee months prior to study\n\n          -  Signed study consent\n\n        Exclusion Criteria:\n\n          -  Known allergy to substances in MAL or Unguentum M cream.\n\n          -  Previous keloid\n\n          -  Use of topical or systemic photosensitizing drug\n\n          -  Evaluated to not be able to follow treatment protocol"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756313", 
            "org_study_id": "H-4-2012-041"
        }, 
        "intervention": {
            "arm_group_label": "Laser+Methylaminolevulinat", 
            "description": "It's a single arm study. Intervention as described in detailed description.", 
            "intervention_name": "Laser+Methylaminolevulinat", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 24, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "zip": "DK-2400"
                }, 
                "name": "Department of Dermatology, Bispebjerg Hospital"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "1", 
        "other_outcome": {
            "description": "Evaluating skin reactions.", 
            "measure": "Skin reactions", 
            "safety_issue": "Yes", 
            "time_frame": "24h"
        }, 
        "overall_official": {
            "affiliation": "Bispebjerg Hospital", 
            "last_name": "Merete Haedersdal, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Denmark: The National Committee on Health Research Ethics", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Fluorescence Intensity measured with a fluorescence camera.", 
            "measure": "Fluorescence Intensity", 
            "safety_issue": "No", 
            "time_frame": "up to 3 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756313"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Bispebjerg Hospital", 
            "investigator_full_name": "Christina Haak", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Bispebjerg Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bispebjerg Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012"
    }
}